Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 127

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 127
---
ITEM 18. FINANCIAL STATEMENTS

                                                                                                                                Page
------------------------------------------------------------------------------------------------------------------------------------
Index to Consolidated Financial Statements                                                                                      F-1 
Report of Independent Registered Public Accounting Firm (PricewaterhouseCoopers, Melbourne, Australia, Auditor Firm ID: 1379)   F-2 
Consolidated Statements of Financial Position                                                                                   F-4 
Consolidated Statements of Profit or Loss and Other Comprehensive Loss                                                          F-5 
Consolidated Cash Flow Statements                                                                                               F-6 
Consolidated Statements of Changes in Shareholders’ Equity                                                                      F-7 
Notes to Consolidated Financial Statements                                                                                      F-8 
Australian Disclosure Requirements

All press releases, financial reports and other information are available on our website: https://alteritytherapeutics.com/

77

ALTERITY THERAPEUTICS LIMITED

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

                                                                          Page 
                                                                         Number
-------------------------------------------------------------------------------
Report of Independent Registered Public Accounting Firm (ID: 1379)       F-2   
Consolidated Statements of Financial Position                            F-4   
Consolidated Statements of Profit or Loss and Other Comprehensive Loss   F-5   
Consolidated Cash Flow Statements                                        F-6   
Consolidated Statements of Changes in Shareholders’ Equity               F-7   
Notes to Consolidated Financial Statements                               F-8   
F-1

Report of Independent Registered Public Accounting Firm 

To the Board of Directors and Shareholders of Alterity Therapeutics Limited

Opinion on the Financial Statements

We have audited the accompanying consolidated statements of financial position of Alterity Therapeutics Limited and its subsidiaries (the “Company”) as of June 30, 2025 and 2024, and the related consolidated statements of profit or loss and other comprehensive loss, of changes in shareholders’ equity and of cash flows for each of the three years in the period ended June 30, 2025, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2025 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board and Australian equivalents to International Financial Reporting Standards as issued by the Australian Accounting Standards Board.
Basis for Opinion

These consolidated financial statements